New study checks immunotherapy safety in elderly cancer patients
NCT ID NCT03673332
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study was designed to track side effects and quality of life in people aged 70 and older with advanced melanoma or non-small cell lung cancer who are starting immunotherapy. Researchers planned to monitor 40 participants for serious side effects and changes in daily well-being using questionnaires. The study was terminated early, so results are limited.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED OR METASTATIC MELANOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Assistance Publique des Hôpitaux de Marseille
Marseille, Bouches Du Rhône, 13385, France
-
CENTRE Francois Baclesse
Caen, France
-
Centre Georges François Leclerc
Dijon, 21079, France
-
IUCT-Oncopole Institut Claudius Rigaud
Toulouse, France
-
Institut BERGONIE
Bordeaux, France
-
Institut Curie
Paris, France
-
Institut De Cancérologie de l'Ouest
Saint-Herblain, France
-
Institut Du Cancer de Montpellier
Montpellier, 34298, France
-
Institut Paoli-Calmettes
Marseille, Bouches-du Rhône, 13009, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new pill outperform chemotherapy for a Hard-to-Treat lung cancer mutation?
- New drug cocktail shows promise for tough lung cancer
- New drug combo aims to shrink Hard-to-Treat melanoma
- New drug cocktail shows early promise for tough lung cancer
- New combo shows promise for Tough-to-Treat lung cancer